Estrella Immunopharma, Inc.
ESLAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEstrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. Valued at $34.4M, ESLA is a micro-cap name in its sector. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Market Cap
$34.4M
Beta
0.86
P/E (TTM)
—
P/E (Fwd)
-2.50
EPS (TTM)
$-0.31
EPS (Fwd)
$-0.32
ROE
—
ROA
-271.5%
Cash
$1.9M
Total Debt
$0
Free CF
-$2.7M
52W Change
-8.5%
Annual Financials
Cash vs Debt
Where ESLA stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ESLA finished 35.43% below its 150-day moving average ($1.27) and 42.66% below its 200-day moving average ($1.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ESLA overbought or oversold?
At the July 15, 2026 close, ESLA's RSI(14) was 32.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Estrella Immunopharma, Inc. reports $1.9M in cash and $0 in total debt. Free cash flow is running at -$2.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Estrella Immunopharma, Inc.'s trajectory.